Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S Wolinsky

Showing results (301-310 of 331) with videos related to

Pageof 34
Sort By:
Multiple Sclerosis (Houndmills, Basingstoke, England)|April 16, 2025
Short- and long-term effects of early versus delayed treatment with ocrelizumab on cerebellar volume loss in patients with RMS and PPMSDouglas L Arnold, Shannon Kolind, Haz-Edine Assemlal, et al.
CNS Drugs|January 19, 2020
Diroximel Fumarate Demonstrates an Improved Gastrointestinal Tolerability Profile Compared with Dimethyl Fumarate in Patients with Relapsing-Remitting Multiple Sclerosis: Results from the Randomized, Double-Blind, Phase III EVOLVE-MS-2 StudyRobert T Naismith, Annette Wundes, Tjalf Ziemssen, et al.
Annals of Neurology|September 7, 2010
Considerations on discontinuing natalizumab for the treatment of multiple sclerosisJoseph R Berger, Diego Centonze, Giancarlo Comi, et al.
Annals of Neurology|April 18, 1998
Guidelines for using quantitative measures of brain magnetic resonance imaging abnormalities in monitoring the treatment of multiple sclerosisM Filippi, M A Horsfield, H J Adèr, et al.
The New England Journal of Medicine|September 13, 2018
Trial of Fingolimod versus Interferon Beta-1a in Pediatric Multiple SclerosisTanuja Chitnis, Douglas L Arnold, Brenda Banwell, et al.
Annals of Neurology|November 12, 2005
Diagnostic criteria for multiple sclerosis: 2005 revisions to the "McDonald Criteria"Chris H Polman, Stephen C Reingold, Gilles Edan, et al.
Journal of Virology|November 13, 1999
Efficient processing of the immunodominant, HLA-A*0201-restricted human immunodeficiency virus type 1 cytotoxic T-lymphocyte epitope despite multiple variations in the epitope flanking sequencesC Brander, O O Yang, N G Jones, et al.
Annals of Neurology|March 10, 2011
Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteriaChris H Polman, Stephen C Reingold, Brenda Banwell, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|March 6, 2020
Effect of fingolimod on MRI outcomes in patients with paediatric-onset multiple sclerosis: results from the phase 3 PARADIG<i>MS</i> studyDouglas L Arnold, Brenda Banwell, Amit Bar-Or, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|July 8, 2020
Temporal profile of lymphocyte counts and relationship with infections with fingolimod therapy in paediatric patients with multiple sclerosis: Results from the PARADIG<i>MS</i> studyTanuja Chitnis, Brenda Banwell, Lauren Krupp, et al.
Pageof 34

Showing results (301-310 of 331) with videos related to

Sort By:
Pageof 34
Multiple Sclerosis (Houndmills, Basingstoke, England)|April 16, 2025
Short- and long-term effects of early versus delayed treatment with ocrelizumab on cerebellar volume loss in patients with RMS and PPMSDouglas L Arnold, Shannon Kolind, Haz-Edine Assemlal, et al.
CNS Drugs|January 19, 2020
Diroximel Fumarate Demonstrates an Improved Gastrointestinal Tolerability Profile Compared with Dimethyl Fumarate in Patients with Relapsing-Remitting Multiple Sclerosis: Results from the Randomized, Double-Blind, Phase III EVOLVE-MS-2 StudyRobert T Naismith, Annette Wundes, Tjalf Ziemssen, et al.
Annals of Neurology|September 7, 2010
Considerations on discontinuing natalizumab for the treatment of multiple sclerosisJoseph R Berger, Diego Centonze, Giancarlo Comi, et al.
Annals of Neurology|April 18, 1998
Guidelines for using quantitative measures of brain magnetic resonance imaging abnormalities in monitoring the treatment of multiple sclerosisM Filippi, M A Horsfield, H J Adèr, et al.
The New England Journal of Medicine|September 13, 2018
Trial of Fingolimod versus Interferon Beta-1a in Pediatric Multiple SclerosisTanuja Chitnis, Douglas L Arnold, Brenda Banwell, et al.
Annals of Neurology|November 12, 2005
Diagnostic criteria for multiple sclerosis: 2005 revisions to the "McDonald Criteria"Chris H Polman, Stephen C Reingold, Gilles Edan, et al.
Journal of Virology|November 13, 1999
Efficient processing of the immunodominant, HLA-A*0201-restricted human immunodeficiency virus type 1 cytotoxic T-lymphocyte epitope despite multiple variations in the epitope flanking sequencesC Brander, O O Yang, N G Jones, et al.
Annals of Neurology|March 10, 2011
Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteriaChris H Polman, Stephen C Reingold, Brenda Banwell, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|March 6, 2020
Effect of fingolimod on MRI outcomes in patients with paediatric-onset multiple sclerosis: results from the phase 3 PARADIG<i>MS</i> studyDouglas L Arnold, Brenda Banwell, Amit Bar-Or, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|July 8, 2020
Temporal profile of lymphocyte counts and relationship with infections with fingolimod therapy in paediatric patients with multiple sclerosis: Results from the PARADIG<i>MS</i> studyTanuja Chitnis, Brenda Banwell, Lauren Krupp, et al.
Pageof 34